SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 15.1% in December

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 31,400 shares, a decline of 15.1% from the December 15th total of 37,000 shares. Based on an average daily volume of 25,600 shares, the short-interest ratio is presently 1.2 days. Currently, 0.1% of the shares of the company are sold short.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently modified their holdings of SOPH. Principal Financial Group Inc. raised its holdings in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after purchasing an additional 86,764 shares in the last quarter. Green Alpha Advisors LLC boosted its holdings in SOPHiA GENETICS by 119.3% in the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after purchasing an additional 25,686 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares during the period. Finally, Silverberg Bernstein Capital Management LLC purchased a new stake in SOPHiA GENETICS during the fourth quarter worth $70,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH traded up $0.14 during midday trading on Friday, hitting $3.12. The company’s stock had a trading volume of 48,509 shares, compared to its average volume of 28,366. The company has a market cap of $203.97 million, a P/E ratio of -2.86 and a beta of 1.00. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $7.37. The business’s 50 day simple moving average is $3.27 and its 200 day simple moving average is $3.67. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The company had revenue of $15.85 million during the quarter, compared to analysts’ expectations of $15.90 million. During the same quarter in the previous year, the company earned ($0.21) earnings per share. On average, analysts forecast that SOPHiA GENETICS will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.